Answers are grounded in this paper and cite their sources.
Charcot neuroosteoarthropathy (CNO) is characterized with increased osteoclastic activity that can be curbed with antiresorptive agents. Chronic kidney disease (CKD) precludes bisphosphonates but anti-receptor activator of nuclear factor-B ligand (anti-RANKL) antibody, denosumab, can be contemplated in CKD. We investigated denosumab for active CNO of foot in CKD for CNO remission.
No takes yet. Share an insight, caveat, or question.
Rastogi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: